Doç. Dr. ZAFER ARIK

Yayın Ağı

Makaleler 44

1. The lactate dehydrogenase-to-albumin ratio is a prognostic biomarker in extensive-stage small-cell lung cancer

YILMAZ F., Yaşar S., Tatar O. D., Yildirim H. c., Guven D. C., TABAN H., et al.

Acta Medica , cilt.56, sa.3, ss.186-198, 2025 (TRDizin)

2. The association between blood sodium levels and survival in patients treated with immune checkpoint inhibitors

ŞAHİN T. K., GÜVEN D. C., Durukan M., KAVGACI G., KAYGUSUZ Y., ARIK Z., et al.

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS , sa.4, ss.129-137, 2025 (SCI-Expanded)

3. The association between HALP score and survival in patients treated with immune checkpoint inhibitors

ŞAHİN T. K., GÜVEN D. C., Durukan M., BAŞ O., KAYGUSUZ Y., ARIK Z., et al.

EXPERT REVIEW OF ANTICANCER THERAPY , sa.1, ss.81-89, 2025 (SCI-Expanded)

4. Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer

YILMAZ F., YAŞAR S., Tatar O. D., Yildirim H. C., Guven D. C., AKYILDIZ A., et al.

BMC CANCER , cilt.24, sa.1, 2024 (SCI-Expanded, Scopus)

5. Trabectedin for L-Type Sarcoma: A Retrospective Multicenter Study

On S., KÖKSAL B., ARIK Z., Caner B., ERCAN UZUNDAL D., YAZICI O., et al.

CURRENT ONCOLOGY , cilt.31, sa.11, ss.6803-6813, 2024 (SCI-Expanded, Scopus)

6. Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group

AKYILDIZ A., GÜLTEKİN M., YİĞİT E., Demir E., Ismayilov R., AHMED M. A., et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER , cilt.34, ss.1359-1365, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

7. Erken Evre Serviks Kanseri Hastalarında Progresyonun Öngördürücüsü Olarak Nötrofil Lenfosit Oranı

Akyıldız A., Ismayilov R., Arık Z.

Journal of medicine and palliative care (Online) , cilt.5, sa.4, ss.203-207, 2024 (TRDizin)

8. Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab

YILDIRIM H. Ç., Anik H., ATEŞ ÖZDEMİR D., Ismayilov R., AKYILDIZ A., ÇAYIRÖZ K., et al.

BIOMOLECULES AND BIOMEDICINE , cilt.24, sa.4, ss.998-1003, 2024 (SCI-Expanded, Scopus)

9. Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer

Karacin C., Sunar V., Urakci Z., YILMAZ A., Ayhan M., Ersoy M., et al.

Future oncology (London, England) , cilt.20, sa.4, ss.207-214, 2024 (SCI-Expanded, Scopus)

10. Bilateral Testicular Plasmacytoma Preceding Multiple Myeloma with Extramedullary Renal Involvement: A Case Report

KAVGACI G., KÖKSAL B., ARIK Z., BARIŞTA İ., AKIN S.

PLASMATOLOGY , cilt.18, 2024 (ESCI, Scopus)

11. Frontline Management of Advanced Epithelial Ovarian Cancer: A Comprehensive Statement by the Africa Middle East Cancer Inter-group [AMCI]

Seoud M., Ladjeroud A., Jaafar H., Mokhtar M., Ozyilkan O., Alkhayyat S., et al.

Current Women's Health Reviews , cilt.20, sa.1, 2024 (ESCI, Scopus)

12. Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia

AKTAŞ B. Y., ATA E. B., ÇEŞMECİ E., ÇAKIR İ. Y., Coşkunpınar M., TAHILLIOĞLU Y., et al.

Current Oncology , cilt.30, sa.11, ss.9689-9700, 2023 (SCI-Expanded, Scopus)

13. KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer

KUŞ F., Guven D. C., YILDIRIM H. Ç., Chalabiyev E., AKYILDIZ A., Tatar O. D., et al.

Biomarkers in Medicine , cilt.17, sa.7, ss.379-389, 2023 (SCI-Expanded, Scopus)

14. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy

GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.

INTERNATIONAL JOURNAL OF CANCER , cilt.152, ss.679-685, 2023 (SCI-Expanded, Scopus)

15. Comparison of Neoadjuvant Chemotherapy Plus Interval Debulking Surgery and Primary Debulking Surgery in Patients with Stage III and IV Ovarian Carcinoma: A Multicenter Real Life Experience

Yilmaz M., Başak M., Özyükseler D. T., Yildirim M. E., ARIK Z., SALMAN M. C., et al.

Turk Onkoloji Dergisi , cilt.38, sa.3, ss.323-332, 2023 (ESCI, Scopus, TRDizin)

16. Biochemical Response Evaluation on Lymphomas: Proposing a Scoring System

ERDAT E. C., ARIK Z., BARIŞTA İ.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.33, sa.3, ss.170-178, 2023 (SCI-Expanded, Scopus, TRDizin)

17. Leptomeningeal metastasis in primary uterine cervical cancer: a rare case and review of the literature

KAHVECİOĞLU A., Sari S. Y., YILDIRIM H. Ç., ARIK Z., GÜLTEKİN M., YILDIZ F.

Corrosion Science and Technology , cilt.19, sa.3, ss.184-189, 2023 (ESCI, Scopus)

18. Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards

GÜVEN D. C., EROĞLU İ., Ismayilov R., ULUSOYDAN E., AKTEPE O. H., TELLİ DİZMAN G., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.28, sa.8, ss.1807-1811, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

19. The impact of COVID-19 pandemic on nosocomial multidrug-resistant bacterial bloodstream infections and antibiotic consumption in a tertiary care hospital

Metan G., Cuha M. D., Hazirolan G., Dizman G., Tanriverdi E. S., Otlu B., et al.

GMS HYGIENE AND INFECTION CONTROL , cilt.17, 2022 (ESCI) Sürdürülebilir Kalkınma

20. Comparison of weekly methotrexate regimen versus methotrexate folinic acid 8-day regimen for treatment of low-risk gestational trophoblastic neoplasia

Korkmaz V., Sunar V., Akar S., Alinca C. M., ARIK Z., Boran N., et al.

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY , cilt.18, sa.3, ss.326-332, 2022 (SCI-Expanded, Scopus)

21. Frequency of germline BRCA1/2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer

Sunar V., Korkmaz V., Topcu V., Cavdarli B., ARIK Z., Ozdal B., et al.

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY , cilt.18, sa.1, ss.84-92, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

22. Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma

Gurler F., GÜVEN D. C., Aydemir E., SÜTCÜOĞLU O., Inci B. K., ARIK Z., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.52, sa.5, ss.1559-1568, 2022 (SCI-Expanded, Scopus, TRDizin)

23. Ovarian Carcinoma Presenting With a Large Cervical Mass

YILMAZ M. T., GÜRLEK E., GÜLTEKİN M., Kahraman K., SALMAN M. C., USUBÜTÜN A., et al.

CUREUS JOURNAL OF MEDICAL SCIENCE , cilt.14, sa.1, 2022 (ESCI)

24. Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment

GÜRLER F., Ilhan A., GÜVEN D. C., TURHAN O., KURT İNCİ B., SÜTCÜOĞLU O., et al.

ANTI-CANCER DRUGS , cilt.33, sa.1, 2022 (SCI-Expanded, Scopus)

25. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality

GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., et al.

BMJ SUPPORTIVE & PALLIATIVE CARE , 2021 (SCI-Expanded, Scopus)

26. Should Protocols Specific to Histologic Subtypes Be Applied in the Follow-Up of NSCLC?

ARIK Z., ERMAN M.

JOURNAL OF THORACIC ONCOLOGY , cilt.16, sa.10, 2021 (SCI-Expanded, Scopus)

27. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy

GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.

SUPPORTIVE CARE IN CANCER , cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

28. The prognostic significance of microsatellite status and its relationship with tumor-infiltrating lymphocyte in endometrial cancer

Lacin S., TAŞAR KAPAKLI G. E., USUBÜTÜN A., ARIK Z., YÜCE D., SALMAN M. C., et al.

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY , cilt.42, sa.3, ss.541-547, 2021 (SCI-Expanded, Scopus)

29. Multi-institutional validation of the ESMO-ESGO-ESTRO consensus conference risk grouping in Turkish endometrial cancer patients treated with comprehensive surgical staging

GÜLTEKİN M., Guler O. C., Sari S., Yildirim B. A., Onal C., Celik H., et al.

JOURNAL OF OBSTETRICS AND GYNAECOLOGY , cilt.41, sa.3, ss.414-420, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

30. Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic: A Pan-European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe)

GÜLTEKİN M., AK S., AYHAN A., Strojna A., Pletnev A., Fagotti A., et al.

CANCER MEDICINE , cilt.10, sa.1, ss.208-219, 2021 (SCI-Expanded, Scopus)

31. Comparison of Efficacies of Dose Dense Paclitaxel Plus Carboplatin and Conventional Paclitaxel Plus Carboplatin in the Treatment of Epithelial Ovarian Cancer

Sunar V., Korkmaz V., Aslan K., Kose C., Sarici F., ARIK Z., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.31, sa.4, ss.239-245, 2021 (SCI-Expanded, Scopus, TRDizin)

32. Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study Design

GÜVEN D. C., GÜNER G., AKTAŞ B. Y., AKTEPE O. H., TABAN H., ARIK Z.

CLINICAL COLORECTAL CANCER , cilt.19, sa.3, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

33. Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study

Sunar V., Korkmaz V., AKIN S., GÜVEN D. C., ARIK Z., Ates O., et al.

JOURNAL OF BUON , cilt.24, sa.6, ss.2327-2332, 2019 (SCI-Expanded, Scopus)

34. Retrospective Analysis of Gestational Trophoblastic Neoplasia: Single Center Experience

Sunar V., Korkmaz V., ARIK Z., Ozdal B., Engin Ustun Y.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.29, sa.3, ss.168-175, 2019 (SCI-Expanded, Scopus, TRDizin)

35. Cytoreductive Surgery for Intestinal Cancer Patients Metastatic to Ovaries Presenting as Primary Ovarian Cancer

Arik Z., Oz M., DİZDAR Ö., YILDIRIM M. E., OZGU E., TERZIOGLU S. G., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.26, sa.2, ss.110-115, 2016 (SCI-Expanded, Scopus, TRDizin)

36. Molecular subtypes in patients with inflammatory breast cancer; A single center experience

KERTMEN N., BABACAN T., Keskin O., Solak M., Sarici F., AKIN S., et al.

JOURNAL OF BUON , cilt.20, sa.1, ss.35-39, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

37. A systemic late recurrence after the first operation in a patient diagnosed with early-stage breast cancer: the latest recurrence in the literature

Keskin O. D., KERTMEN N., Karakas Y., BABACAN T., ARIK Z., Altundag K., et al.

JOURNAL OF BUON , cilt.20, sa.1, ss.348, 2015 (SCI-Expanded, Scopus)

38. Evaluation of the effect of comorbidity on survival in pancreatic cancer by using "Charlson Comorbidity Index" and "Cumulative Illness Rating Scale"

Kos F. T., Yazici O., Civelek B., Seker M., ARIK Z., AKSOY S., et al.

WIENER KLINISCHE WOCHENSCHRIFT , cilt.126, ss.36-41, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

39. Association between common risk factors and molecular subtypes in breast cancer patients

Turkoz F. P., Solak M., Petekkaya I., Keskin O., KERTMEN N., Sarici F., et al.

BREAST , cilt.22, sa.3, ss.344-350, 2013 (SCI-Expanded, Scopus)

40. Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use

Sendur M. A. N., Aksoy S., Yaman S., Arik Z., Ozdemir N. Y., Zengin N., et al.

MEDICAL ONCOLOGY , cilt.29, sa.4, ss.2601-2605, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

41. Dermatomyositis complicated with a soft tissue sarcoma

Sendur M. A. N., Aksoy S., Yaman S., Arik Z., Kilinc L., Zengin N.

RHEUMATOLOGY INTERNATIONAL , cilt.32, sa.10, ss.3329-3330, 2012 (SCI-Expanded, Scopus)

42. Can all beta blockers improve the breast cancer survival?

Sendur M. A. N., Aksor S., Yaman S., Arik Z., Altundag K.

BREAST , cilt.21, sa.1, ss.107-108, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

43. Is There an Association between Blood Group and Survival in Pancreatic Cancer?

Kos F. T., Civelek B., Seker M. M., ARIK Z., AKSOY S., Uncu D., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.13, sa.12, ss.6151-6153, 2012 (SCI-Expanded, Scopus)

44. Breast Cancer in a Patient with Agnogenic Myeloid Metaplasia

ARIK Z., OZKAN C., Ozdemir E., ALTUNDAG K.

SOUTHERN MEDICAL JOURNAL , cilt.103, sa.10, ss.1075-1076, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 15

1. The efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: A multicenter study by the Turkish Oncology Group (TOG)

Akyildiz A., GÜLTEKİN M., Yigit E., Demir E., Ismayilov R., AHMED M. A., et al.

Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)

2. Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe experience

AKSOY S., DEĞİRMENCİLER R. F., AKTAŞ B. Y., Guven D. C., AKTEPE O. H., Guner G., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri) Sürdürülebilir Kalkınma

3. Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital

Guven D. C., AKTEPE O. H., Berk Z., Guner G., Taban H., AKTAŞ B. Y., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri)

4. Is microsatellite instability a negative prognostic factor in early stage endometrial cancer patients?

Lacin S., Tasar G. E., Usubutun A., Arik Z., Karakas Y., Yuce D., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri) Sürdürülebilir Kalkınma

5. TRASTUZUMAB KARDİYOTOKSİSİTESİNİ İMMUNGLOBULİN /- STEROİD UYGULAMASI ÖNLEYEBİLİR Mİ?, TAVŞAN MODELİ HAYVAN DENEYİ

KERTMEN N., AKSOY S., ERMİŞ D. Y., KESKİN Ö., SOLAK M., ARIK Z., et al.

22. UKK, Türkiye, 19 - 23 Nisan 2017, (Özet Bildiri)

6. Cytoreductive surgery for intestinal cancer patients metastatic to the adnexal presenting as primary ovarian cancer.

Arik Z., Dizdar O., Yildirim M. E., Ozgu E., Oz M., Terzioglu S. G., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) Sürdürülebilir Kalkınma

7. Which sequence prevents the heart from trastuzumab and anthracycline toxicity: Electron microscopy study in rats

Aksoy S., Kertmen N., ÜNER A., Sargon M., Ozkayar O., Keskin O., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)

8. Temporal changes in the survival of metastatic renal cell cancer patients and the impact of targeted agents: Single center experience

Erman M., Arik Z., Kilickap S., Bilen C. Y., Yazici S., Akdogan B., et al.

Genitourinary Cancers Symposium, San-Francisco, Kostarika, 30 Ocak - 01 Şubat 2014, cilt.32, (Özet Bildiri) Sürdürülebilir Kalkınma

9. Arrhythmias during and after zoledronic acid infusion patients with bone metastasis.

Yazici O., Aksoy S., Ucar O., Ozdemir N., Demir M., Sendur M. A. N., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)

10. Clinicopathologic characteristics of pure papillary breast carcinoma

Turkoz F. P., Solak M., Keskin O., Arik Z., Arslan C., Kertmen N., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)

11. Inflammatory markers in metastatic breast cancer.

Sahin U., Petekkaya H., Gecmez G., Babacan T., Roach E. C., Sarici S. F., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri) Sürdürülebilir Kalkınma

12. Variations of the ER, PR, and HER2 expression status according to operation day in breast cancer patients.

Arik Z., Aksoy S., Sendur M. A. N., Yaman S., Altundag K.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri) Sürdürülebilir Kalkınma

13. Administration of contrast media just before the cisplatin-based chemotherapy increases the cisplatin-induced nephrotoxicity.

Sendur M. A. N., Aksoy S., Yaman S., Kos F. T., Arik Z., Civelek B., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)

14. Does total breastfeeding time influence the clinicopathologic characteristics and prognosis in breast cancer patients?

Yaman S., Aksoy S., Sendur M. A. N., Arik Z., Ozdemir N., Zengin N., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri) Sürdürülebilir Kalkınma

15. Demographic and clinicopathologic characteristics of breast cancer patients with history of oral alendronate use

Aksoy S., Sendur M. A. N., Yaman S., Arik Z., Ozdemir N., Zengin N., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri) Sürdürülebilir Kalkınma

Kitaplar 1

1. Kastrasyona dirençli prostat kanseri tedavisi

ERMAN M., ARIK Z.

Üroonkoloji Kitabı, , Editör, Nobel, 2018

Metrikler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

200

H-İndeks (WoS)

Atıf (Scopus)

116

H-İndeks (Scopus)

Proje

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Proje

Açık Erişim